Top Markets
#1 Velas Velas +480.91%
#2 Siren Siren +109.58%
#3 NEW X CEO IS BACK NEW X CEO IS BACK +109.20%
#4 Venom Venom +45.46%
#5 Gigachad Gigachad +23.69%
#6 Ontology Ontology +20.18%
#7 Scor Scor +17.06%
#8 Dacxi Dacxi +16.49%
#9 Strategic Oil Supply Strategic Oil Supply +15.04%
#10 TRIA TRIA +14.71%
Coin of the day
Velas Velas
設定
言語
日本
通貨
USD
テーマ
Noxopharm Limited Noxopharm Limited

Noxopharm Limited

NOX
株式のランク #17276
Noxopharm Limited, a drug development company, focuses on developing treatment... Noxopharm Limited, a drug development company, focuses on developing treatment options for a range of solid tumor cancers and septic shock in Australia and internationally. It primarily develops Veyonda, which is an adjuvant therapy in chemotherapy and radiotherapy for the treatment of late-stage cancers. The company also develops DARRT program that is in Phase 1b/2a for the treatment of metastatic castration-resistant prostate cancer and other solid tumors; LuPIN with combined therapy of Veyonda and 177Lu-PSMA-617 for the treatment of late-stage prostate cancer; IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types; and chemotherapy enhancement program (CEP) combined with carboplatin for patients with refractory solid tumors in the breast, head and neck, lung, prostate, and ovaries. In addition, it develops NOXCOVID Program, a dose escalation and dose expansion study of NOX66 for the treatment of COVID-19 infection. Further, the company develops programs to treat pancreatic cancer and glioblastoma. Noxopharm Limited has a collaboration with Hudson Institute of Medical Research and The Australian National University for the research and development of therapeutic drug against inflammatory disorders. The company was incorporated in 2015 and is based in Chatswood, Australia.
株価
$0.0416118
時価総額
$12.78M
変化（1日）
1.72%
変化（1年）
-22.01%
国
AU
取引 Noxopharm Limited (NOX)

カテゴリー

Healthcare
Noxopharm Limited（NOX）の収益
Dec 2025 時点の収益 TTM: $1.11M
Noxopharm Limited の最新の財務報告によると、現在の収益 (TTM) は $1.11M です。2024 年には $1.60M の収益があり、これは 2023 年の $4.00M と比較して 減少 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Noxopharm Limited の収益履歴（2016 ～ 2026）
各年末の収益
年 収益 変化
2026 (TTM) $1.11M -40.21%
2025 $1.86M 15.87%
2024 $1.60M -59.98%
2023 $4.00M 6.95%
2022 $3.74M -10.96%
2021 $4.21M -26.42%
2020 $5.71M 116.95%
2019 $2.63M 288.04%
2018 $678.81K 597.95%
2017 $97.26K 0.00%
2016 0.00 0.00%
同業他社の収益
企業 収益 収益の差 国
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 $48.44B 4,362,149.84%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.04B 1,084,093.51%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 $14.34B 1,291,639.69%
US
UCB SA UCB SA
UCB SA
UCB.BR
 $9.08B 817,860.65%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B 1,413,432.75%
AU